SGLT2 Inhibitors: The Latest New Kids on the Block!
Everything in the world of diabetes is moving fast these days. Over the last few months, we have received extensive new information regarding the burden of diabetes and suggested changes in treatment strategies. Specifically, in the December 2014 issue of Diabetes Care, we reported startling new statistics about the rising costs associated with diabetes and prediabetes. The economic burden associated with diagnosed and undiagnosed diabetes, gestational diabetes mellitus, and prediabetes was estimated to be 48% higher than that reported in 2007. For 2012, the estimated total burden exceeded $322 billion, comprising $244 billion in excess medical costs and $78 billion in reduced productivity. Following the release of these economic statistics there came further proposals regarding strategies for managing diabetes. In the January 2015 issue of Diabetes Care, and coordinated with a release in Diabetologia, there was an update to the 2012 position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) on the management of hyperglycemia.